Curated News
By: NewsRamp Editorial Staff
June 18, 2026
AML Therapeutics Market to Triple to $10.1B by 2036
TLDR
- Fact.MR reports AML therapeutics market to double to $10.1B by 2036, with targeted therapies leading at 36% share.
- Market growth driven by genomics-driven treatment strategies, molecular diagnostics, and mutation-specific therapies like FLT3 inhibitors.
- Precision medicine in AML improves patient outcomes by targeting genetic mutations, reducing toxicity and offering new hope.
- India is the fastest-growing AML market at 11.8% CAGR, fueled by expanding cancer care and diagnostic access.
Impact - Why it Matters
This news matters because AML is a devastating blood cancer with historically limited treatment options. The projected market growth reflects a paradigm shift toward precision medicine, offering new hope for patients through targeted therapies that are more effective and less toxic. For healthcare providers and investors, this underscores the urgent need to adopt molecular diagnostics and personalized treatment pathways. Patients stand to benefit from improved survival rates and quality of life, especially those with relapsed or refractory disease who previously had few alternatives. The rapid growth in emerging markets like India and China also signals expanding global access to advanced cancer care.
Summary
The global Acute Myeloid Leukemia (AML) Therapeutics Market is set to nearly triple from USD 3.8 billion in 2025 to USD 10.1 billion by 2036, growing at a CAGR of 9.2%, according to a new report by Fact.MR, a leading market research and competitive intelligence provider. The global Acute Myeloid Leukemia (AML) Therapeutics Market is being revolutionized by precision medicine, with targeted therapies emerging as the leading drug class, accounting for 36% of market share. Key players such as AbbVie Inc., Genentech (Roche), Astellas Pharma Inc., Syndax Pharmaceuticals, and Kura Oncology are investing heavily in mutation-specific treatments and combination regimens. Newly diagnosed AML represents the largest patient segment (48% share), while hospitals dominate as the primary treatment setting (55% share), and hospital pharmacies lead sales channels (49% share).
The transformation is driven by genomics-driven treatment strategies that shift from traditional chemotherapy toward personalized medicine. Molecular diagnostics and mutation-based selection for targets like FLT3 and NPM1 are improving outcomes and reducing recurrence. The relapsed and refractory AML segment is creating new opportunities with oral targeted therapies and menin inhibitors. India is the fastest-growing country at 11.8% CAGR, followed by China at 10.9% CAGR, while the United States grows at 8.7% CAGR. The market is projected to create an absolute dollar opportunity of USD 5.9 billion, expanding nearly 2.4 times its current value.
According to Shambhu Nath Jha, Principal Consultant at Fact.MR, the future of AML treatment will depend on molecular testing, precision treatment selection, and therapies that balance efficacy with tolerability. The report highlights that South Asia and East Asia are emerging high-growth regions due to expanding cancer care infrastructure and access to diagnostics. Despite challenges like treatment costs and reimbursement constraints, the long-term outlook remains highly positive as innovation reshapes the global hematology treatment landscape.
Source Statement
This curated news summary relied on content disributed by 24-7 Press Release. Read the original source here, AML Therapeutics Market to Triple to $10.1B by 2036
